Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  selumetinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 43 for your search:
Start Over
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1344C00001, NCT01974752
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: ABC-04, 2010-018522-39, NCT01242605
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00012, NCT00372788
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00008, NCT00372944
Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2009-00604, GOG-0239, CDR0000563965, U10CA027469, NCT00551070
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00251, OSU 07056, CDR0000573452, N01CM62208, N01CM62207, 07056, 7932, NCT00553332
AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01056, CDR0000574262, LOI 7918, 7918, N01CM62201, N01CM62203, N01CM62208, P30CA076292, MCC-15305, MCC-LOI-7918, NCT00559949
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00250, 15455B, N01CM62209, N01CM62201, UCCRC-15455B, 7925, NCT00588809
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01164, MSKCC-09003, CDR0000637669, 09-003, 8252, N01CM62206, P30CA008748, NCT00866177
Selumetinib in Cancers With BRAF Mutations
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00576, CDR642346, 09-005, 8281, N01CM62206, P30CA006516, U01CA062490, NCT00888134
Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00016, NCT00890825
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00006, NCT00936221
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01958, CDR0000651456, GOG-0229H, U10CA027469, NCT01011933
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02929, CDR669144, NCI-8631, 10-C-0079, 8631, N01CM00071, N01CM00100, N01CM62208, P30CA076292, NCT01085214
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D9010C00009, AGICC 09CRC02, NCT01116271
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01411, CDR0000674866, 10-053, 8443, N01CM00070, N01CM00071, N01CM00099, N01CM00100, N01CM62206, N01CM62208, P30CA008748, U01CA132123, MSKCC-10053, NCT01143402
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SAKK 21/08, SWS-SAKK-21/08, EUDRACT-2010-019965-27, EU-21046, CDR0000680800, NCT01160718
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2011-02532, CDR0000685408, CHNMC-PHII-95, NCCN-T06, PHII-95, 8412, N01CM00038, P30CA033572, NCT01206140
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01266, CDR0000686634, UCSF-10454, 10454, 8598, N01CM00070, R21CA149939, P30CA082103, USCF-10454, NCT01222689
Docetaxel With or Without AZD6244 in Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: OCTO_015, NCT01256359
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110117, 11-C-0117, NCT01333475
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01993, SWOG-S1115, CDR0000737878, S1115, U10CA180888, U10CA032102, NCT01658943
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1532C00005, NCT00463814
Start Over